NMN (Nicotinamide Mononucleotide)

nicotinamide mononucleotide

NMN is a direct NAD+ precursor that became the face of the longevity-supplement boom after David Sinclair's mouse studies. In October 2022 the FDA quietly removed it from the supplement category — it is now in legal limbo while remaining widely available online.

NAD+ precursorEvidence C
⚠ Not medical advice.Not medical advice. This page is educational. Discuss with your physician before starting, changing, or stopping any medication.

Why it matters

NMN had a remarkable five-year run as the flagship longevity supplement. Sinclair lab mouse studies and Imai lab work (Mills 2016) showed compelling age-related rescue of metabolic and physiological function. The Yoshino 2021 trial in Science showed improved muscle insulin sensitivity in prediabetic postmenopausal women. Consumer demand exploded; brands proliferated; podcasts amplified. Then in October 2022 the FDA issued a quiet but decisive ruling: NMN had been investigated as a drug (an IND was filed) before any company tried to market it as a supplement, which triggered the IND exclusion clause of DSHEA — meaning NMN cannot lawfully be sold as a dietary supplement in the US. Enforcement has been patchy, and product remains widely available, but the legal status is genuinely unresolved. From a science perspective: NMN raises some NAD+ metabolites in blood, but tissue distribution in humans is poorly characterized; long-term safety is unknown; the theoretical cancer-proliferation concern has not been studied at scale. NMN may turn out to be useful. It is not yet established as so, and the regulatory situation makes responsible recommendation difficult.

Uses

Off-label (educational only)
  • Age-related NAD+ decline / general longevityweak
  • Metabolic health / insulin sensitivityweak
  • Exercise capacity in older adultsweak
  • Mitochondrial dysfunctionweak

Dosing

Label dose
No FDA-approved label dose. NMN is not an approved drug.
Off-label / biohacker dose
Most human trials and consumer protocols use 250-1000 mg orally per day, typically in the morning on an empty stomach. The optimal dose, duration, and long-term safety are not established.
Titration: Start at 250 mg to assess tolerance. Sublingual and liposomal formulations claim higher bioavailability but evidence is thin. Cycling protocols (5 days on, 2 off) are common but not evidence-based.
When to take: Morning, on an empty stomach. NMN can be mildly stimulating; avoid evening dosing.

Side effects & warnings

Common
  • Mild nausea
  • Flushing (less than niacin)
  • Mild GI upset
  • Headache
Uncommon but serious
  • Insomnia if dosed late
  • Skin flushing
  • Mild blood pressure changes
Serious warnings
Long-term safety in humans is unknown. The theoretical concern that elevated NAD+ could fuel cancer cell proliferation has not been resolved by clinical data. Sirtuin activation is not unambiguously beneficial — context matters. Patients with active malignancy or cancer history should not take NMN without oncology consultation.

Biomarkers affected

fasting insulin
decrease
Yoshino 2021 showed improved muscle insulin sensitivity in prediabetic postmenopausal women; effect size modest.
Evidence: weak
hscrp
variable
Anecdotal reports of mild anti-inflammatory effects; not confirmed in well-powered RCTs.
Evidence: anecdotal
igf 1
variable
Some human trials show small IGF-1 shifts during NMN supplementation; direction inconsistent across studies.
Evidence: weak

Monitoring

No established monitoring biomarkers. Some users track HRV, fasting glucose, and subjective energy. Direct NAD+ measurement in blood is research-grade and not standardized.

The honest risk picture

## Regulatory Status (READ FIRST) In **October 2022**, the FDA notified manufacturers that NMN does not meet the statutory definition of a dietary supplement under DSHEA because it was the subject of an IND (investigational new drug application) before any company marketed it as a supplement. This invokes the "IND exclusion clause." Legal practical implications: - NMN cannot lawfully be sold as a dietary supplement in the US. - Enforcement has been inconsistent — product remains widely available online, especially from overseas suppliers. - Several major US retailers (including Amazon for a period) have removed NMN from listings. - In the EU, NMN lacks novel food authorization. - Status is genuinely unresolved and may change. ## Serious Risks **Theoretical cancer concern:** NAD+ supports proliferation in all cells, including malignant ones. While no clinical study has shown NMN promotes tumor growth, long-term data are absent. Patients with active or recent cancer should not take NMN without oncology consultation. **Long-term safety unknown.** Human exposure beyond 12 months is essentially uncharacterized. ## Practical Cautions - **Product quality varies enormously.** NMN is unstable and many supplements assay at <50% of label claim. Third-party COAs are essential. - **Bioavailability claims are largely unvalidated.** Sublingual, liposomal, and time-release formulations charge premium prices for unproven advantages. - **Pregnancy and breastfeeding:** No safety data — avoid. - **Drug interactions:** Not well characterized. Theoretical interaction with sirtuin-modulating drugs and chemotherapy.

Practical context

Cost (US, retail)
$60/mo
Legality
IMPORTANT: In October 2022 the FDA notified manufacturers that NMN is not a lawful dietary supplement ingredient in the United States because it was previously studied as an investigational new drug (under the IND drug exclusion clause). NMN can no longer be marketed as a supplement in the US, although enforcement has been inconsistent and product remains widely available. In the EU, NMN does not have novel food authorization. Legal status is in flux — check current regulations before purchasing.
Interactions
false

FAQ

Is NMN legal in the US?+
As of October 2022, the FDA determined NMN cannot be sold as a dietary supplement because it had been investigated as a drug first (IND exclusion). Enforcement has been inconsistent and product remains available online, but the legal status is unsettled. Some retailers have removed NMN from US listings.
Does NMN actually raise NAD+ in humans?+
Some trials show modest increases in blood NAD+ metabolites. Tissue-level effects in humans remain poorly characterized. The chain from oral NMN to systemic NAD+ involves substantial first-pass metabolism.
NMN vs NR — which is better?+
In humans there is no head-to-head trial showing clear superiority. NR has more clinical data and a legal supplement pathway in the US. NMN has stronger animal data. Both are NAD+ precursors with similar logic.
Could NMN fuel cancer growth?+
This is a legitimate theoretical concern that has not been resolved. NAD+ supports cell proliferation, including malignant cells. Patients with cancer history should not take NMN without oncology guidance.
References (5)+
  1. .
  2. .
  3. .
  4. .
  5. .
The prime report

Weekly performance intelligence.

New studies, protocols, and optimization frameworks delivered every Monday. No fluff, no motivation quotes — only what moves the needle.

No spam. Unsubscribe anytime.